



British Pharmacopoeia

British Pharmacopoeia Commission Secretariat
MHRA, 10 South Colonnade
Canary Wharf, London
E14 4PU, United Kingdom
pharmacopoeia.com

Date: 12 September 2024

TO WHOM IT MAY CONCERN

ESOMEPRAZOLE FOR INJECTION BP 2024

ASSAY

It has come to our attention that the mobile phase in the Assay test for Esomeprazole for Injection in the BP2024 requires a correction. The mobile phase preparation will be amended as follows, the changed text has been highlighted:

MOBILE PHASE

Solution D Dilute a mixture of 10.5 volumes of 1M sodium dihydrogen orthophosphate monohydrate and 60 volumes of 0.5M disodium hydrogen orthophosphate dihydrate to 1000 volumes with water. Adjust to pH 7.3 with orthophosphoric acid or 10M sodium hydroxide.

35 volumes of acetonitrile, 50 volumes of solution D and dilute to 100 volumes with water.

The monograph will therefore be revised to reflect these changes in a future publication.

Please accept this as a notice of intent to amend the monograph on behalf of the British Pharmacopoeia Commission. This letter is for information only and does not represent a legally-enforceable standard. The revised monograph will be published in a future edition of the British Pharmacopoeia - the current target publication is the BP 2026, which will come into force on 1st January 2026.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat (BPCOM@mhra.gov.uk).

Yours faithfully,

MR STEVE HOARE

Secretary & Scientific Director

Email: BPCOM@mhra.gov.uk